FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163087283> ?p ?o ?g. }

• W2163087283 endingPage "746" @default.
• W2163087283 startingPage "739" @default.
• W2163087283 abstract "The chemotherapeutic agent etoposide is a topoisomerase II inhibitor widely used for cancer therapy. Low-dose oral etoposide, administered at close regular intervals, has potent anti-tumor activity in patients who are refractory to intravenous etoposide; however, the mechanism remains unclear. Since endothelial cells may be more sensitive than tumor cells to chemotherapy agents, we determined the effects of etoposide alone and in combination with oral cyclooxygenase-2 inhibitors and peroxisome-proliferator activated receptor γ ligands on angiogenesis and tumor growth in xenograft tumor models. Optimal anti-angiogenic (metronomic) and anti-tumor doses of etoposide on angiogenesis, primary tumor growth and metastasis were established alone and in combination therapy. Etoposide inhibited endothelial and tumor cell proliferation, decreased vascular endothelial growth factor (VEGF) production by tumor cells and suppressed endothelial tube formation at non-cytotoxic concentrations. In our in vivo studies, oral etoposide inhibited fibroblast growth factor 2 and VEGF-induced corneal neovascularization, VEGF-induced vascular permeability and increased levels of the endogenous angiogenesis inhibitor endostatin in mice. In addition, etoposide inhibited Lewis lung carcinoma (LLC) and human glioblastoma (U87) primary tumor growth as well as spontaneous lung metastasis in a LLC resection model. Furthermore, etoposide had synergistic anti-tumor activity in combination with celecoxib and rosiglitazone, which are also oral anti-angiogenic and anti-tumor agents. Etoposide inhibits angiogenesis in vitro and in vivo by indirect and direct mechanisms of action. Combining etoposide with celecoxib and rosiglitazone increases its efficacy and merits further investigation in future clinical trials to determine the potential usefulness of etoposide in combinatory anti-angiogenic chemotherapy." @default.
• W2163087283 created "2016-06-24" @default.
• W2163087283 creator A5014909897 @default.
• W2163087283 creator A5023156067 @default.
• W2163087283 creator A5045261329 @default.
• W2163087283 creator A5060208068 @default.
• W2163087283 creator A5072918929 @default.
• W2163087283 creator A5075631226 @default.
• W2163087283 creator A5088978035 @default.
• W2163087283 date "2010-01-01" @default.
• W2163087283 modified "2023-10-17" @default.
• W2163087283 title "Inhibition of tumor angiogenesis by oral etoposide" @default.
• W2163087283 cites W1722373994 @default.
• W2163087283 cites W1967150708 @default.
• W2163087283 cites W1967587727 @default.
• W2163087283 cites W1972732503 @default.
• W2163087283 cites W1975832276 @default.
• W2163087283 cites W1979876194 @default.
• W2163087283 cites W1984632902 @default.
• W2163087283 cites W1989206745 @default.
• W2163087283 cites W1995311580 @default.
• W2163087283 cites W1997062281 @default.
• W2163087283 cites W2001676296 @default.
• W2163087283 cites W2015941109 @default.
• W2163087283 cites W2028762072 @default.
• W2163087283 cites W2029883816 @default.
• W2163087283 cites W2042921713 @default.
• W2163087283 cites W2058035682 @default.
• W2163087283 cites W2059294866 @default.
• W2163087283 cites W2072928113 @default.
• W2163087283 cites W2072970794 @default.
• W2163087283 cites W2076424556 @default.
• W2163087283 cites W2078258668 @default.
• W2163087283 cites W2080237506 @default.
• W2163087283 cites W2100849207 @default.
• W2163087283 cites W2114592067 @default.
• W2163087283 cites W2119018891 @default.
• W2163087283 cites W2144502394 @default.
• W2163087283 cites W2161889463 @default.
• W2163087283 cites W2164563042 @default.
• W2163087283 cites W2165967358 @default.
• W2163087283 cites W2168843129 @default.
• W2163087283 cites W2169965478 @default.
• W2163087283 cites W2170636961 @default.
• W2163087283 cites W2209064902 @default.
• W2163087283 cites W2314794980 @default.
• W2163087283 cites W240337737 @default.
• W2163087283 cites W2793323124 @default.
• W2163087283 cites W4240908764 @default.
• W2163087283 cites W1975408515 @default.
• W2163087283 doi "https://doi.org/10.3892/etm.2010.127" @default.
• W2163087283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3445956" @default.
• W2163087283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22993597" @default.
• W2163087283 hasPublicationYear "2010" @default.
• W2163087283 type Work @default.
• W2163087283 sameAs 2163087283 @default.
• W2163087283 citedByCount "40" @default.
• W2163087283 countsByYear W21630872832012 @default.
• W2163087283 countsByYear W21630872832013 @default.
• W2163087283 countsByYear W21630872832014 @default.
• W2163087283 countsByYear W21630872832015 @default.
• W2163087283 countsByYear W21630872832016 @default.
• W2163087283 countsByYear W21630872832017 @default.
• W2163087283 countsByYear W21630872832018 @default.
• W2163087283 countsByYear W21630872832019 @default.
• W2163087283 countsByYear W21630872832020 @default.
• W2163087283 countsByYear W21630872832021 @default.
• W2163087283 countsByYear W21630872832022 @default.
• W2163087283 countsByYear W21630872832023 @default.
• W2163087283 crossrefType "journal-article" @default.
• W2163087283 hasAuthorship W2163087283A5014909897 @default.
• W2163087283 hasAuthorship W2163087283A5023156067 @default.
• W2163087283 hasAuthorship W2163087283A5045261329 @default.
• W2163087283 hasAuthorship W2163087283A5060208068 @default.
• W2163087283 hasAuthorship W2163087283A5072918929 @default.
• W2163087283 hasAuthorship W2163087283A5075631226 @default.
• W2163087283 hasAuthorship W2163087283A5088978035 @default.
• W2163087283 hasBestOaLocation W21630872831 @default.
• W2163087283 hasConcept C121608353 @default.
• W2163087283 hasConcept C126322002 @default.
• W2163087283 hasConcept C2776694085 @default.
• W2163087283 hasConcept C2777847059 @default.
• W2163087283 hasConcept C2778119113 @default.
• W2163087283 hasConcept C2779013556 @default.
• W2163087283 hasConcept C2780394083 @default.
• W2163087283 hasConcept C502942594 @default.
• W2163087283 hasConcept C71924100 @default.
• W2163087283 hasConcept C98274493 @default.
• W2163087283 hasConceptScore W2163087283C121608353 @default.
• W2163087283 hasConceptScore W2163087283C126322002 @default.
• W2163087283 hasConceptScore W2163087283C2776694085 @default.
• W2163087283 hasConceptScore W2163087283C2777847059 @default.
• W2163087283 hasConceptScore W2163087283C2778119113 @default.
• W2163087283 hasConceptScore W2163087283C2779013556 @default.
• W2163087283 hasConceptScore W2163087283C2780394083 @default.
• W2163087283 hasConceptScore W2163087283C502942594 @default.
• W2163087283 hasConceptScore W2163087283C71924100 @default.
• W2163087283 hasConceptScore W2163087283C98274493 @default.

• next